Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ANGO | Common Stock | Options Exercise | $0 | +4.44K | +11.67% | $0.00 | 42.5K | Jul 17, 2024 | Direct | F1 |
transaction | ANGO | Common Stock | Tax liability | -$18.4K | -2.49K | -5.85% | $7.40 | 40K | Jul 17, 2024 | Direct | F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ANGO | Performance Right | Options Exercise | $0 | +5.9K | $0.00* | 0 | Jul 17, 2024 | Common Stock | 5.9K | Direct | F3 |
Id | Content |
---|---|
F1 | This acquisition of 4,439 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 21, 2021. |
F2 | The exempt disposition of 2,485 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 21, 2021. |
F3 | On July 21, 2021, the reporting person received a target grant of 5,903 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 4,439 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited. |